CONTE, Pierfranco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 43.775
AS - Asia 18.623
EU - Europa 17.946
SA - Sud America 2.726
AF - Africa 383
Continente sconosciuto - Info sul continente non disponibili 382
OC - Oceania 44
Totale 83.879
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 43.058
GB - Regno Unito 5.569
SG - Singapore 5.384
CN - Cina 5.124
IT - Italia 4.046
HK - Hong Kong 2.273
BR - Brasile 2.097
VN - Vietnam 1.742
SE - Svezia 1.504
DE - Germania 1.294
BD - Bangladesh 1.207
UA - Ucraina 1.114
FI - Finlandia 1.090
IE - Irlanda 929
TR - Turchia 768
RU - Federazione Russa 651
FR - Francia 629
KR - Corea 459
IN - India 425
BG - Bulgaria 395
CA - Canada 345
ID - Indonesia 242
AR - Argentina 204
MX - Messico 171
IQ - Iraq 138
JP - Giappone 130
NL - Olanda 122
EC - Ecuador 99
ZA - Sudafrica 97
PL - Polonia 92
AE - Emirati Arabi Uniti 91
ES - Italia 88
CO - Colombia 86
BE - Belgio 79
PK - Pakistan 79
VE - Venezuela 67
PH - Filippine 61
MY - Malesia 60
CL - Cile 58
UZ - Uzbekistan 53
SA - Arabia Saudita 51
PY - Paraguay 48
MA - Marocco 46
AU - Australia 42
LT - Lituania 42
JM - Giamaica 40
EG - Egitto 38
NP - Nepal 37
CR - Costa Rica 36
CZ - Repubblica Ceca 35
KE - Kenya 35
AT - Austria 34
JO - Giordania 32
TH - Thailandia 31
TN - Tunisia 29
AL - Albania 27
IR - Iran 27
AZ - Azerbaigian 25
ET - Etiopia 25
HN - Honduras 25
HU - Ungheria 25
TW - Taiwan 24
UY - Uruguay 24
RO - Romania 23
DZ - Algeria 22
RS - Serbia 21
BO - Bolivia 20
CH - Svizzera 20
DO - Repubblica Dominicana 20
PE - Perù 20
IL - Israele 19
PT - Portogallo 18
KZ - Kazakistan 17
OM - Oman 17
GR - Grecia 16
LB - Libano 16
NG - Nigeria 16
SN - Senegal 14
NI - Nicaragua 13
SI - Slovenia 13
TT - Trinidad e Tobago 13
SK - Slovacchia (Repubblica Slovacca) 12
BH - Bahrain 11
CI - Costa d'Avorio 10
EU - Europa 10
KG - Kirghizistan 10
PA - Panama 10
QA - Qatar 10
SY - Repubblica araba siriana 10
MD - Moldavia 9
AM - Armenia 8
BW - Botswana 8
PR - Porto Rico 8
PS - Palestinian Territory 8
AO - Angola 7
BB - Barbados 7
DK - Danimarca 7
GT - Guatemala 7
MK - Macedonia 7
NO - Norvegia 7
Totale 83.382
Salva come PNG Salva come JPEG
Città #
Fairfield 4.146
Southend 3.791
Ashburn 3.772
Singapore 3.485
Santa Clara 3.039
Woodbridge 3.038
Houston 2.618
Jacksonville 2.283
Hong Kong 2.240
Chandler 2.016
Ann Arbor 1.732
Dearborn 1.563
Seattle 1.530
Wilmington 1.516
Hefei 1.513
Cambridge 1.366
San Jose 1.039
Beijing 1.022
London 937
Dublin 923
Nyköping 821
Council Bluffs 780
Los Angeles 705
Helsinki 703
Modena 640
The Dalles 633
Chicago 608
Ho Chi Minh City 581
New York 532
Milan 446
Princeton 442
San Diego 432
Seoul 426
Hanoi 394
Sofia 379
Eugene 377
Izmir 363
Lauterbourg 318
Columbus 288
Buffalo 278
Salt Lake City 225
Shanghai 208
Des Moines 204
Rome 204
Moscow 203
São Paulo 194
Dallas 182
Boardman 157
Jakarta 150
Falls Church 142
Munich 138
Frankfurt am Main 121
Elk Grove Village 116
Tampa 113
Bologna 105
Norwalk 94
Phoenix 94
Naples 93
Tokyo 92
Orem 86
Guangzhou 84
Da Nang 80
Atlanta 74
Brussels 71
Haiphong 71
Toronto 68
Turin 68
Denver 65
Miano 65
Florence 64
Lancaster 63
Chennai 62
Mexico City 62
Warsaw 62
Redwood City 58
Rio de Janeiro 57
Dong Ket 54
Fremont 53
Brooklyn 52
Sterling 52
Belo Horizonte 51
Nanjing 51
Porto Alegre 51
Bremen 49
Kunming 49
Bari 46
Redondo Beach 46
Falkenstein 45
Montreal 45
Tashkent 44
Verona 44
Baghdad 41
Brasília 41
Mumbai 40
North Bergen 40
Kilburn 38
Miami 38
Palermo 38
Philadelphia 38
Stockholm 38
Totale 58.794
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.167
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 492
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 447
Rigenerand srl - Spin off Università di Modena e Reggio Emilia 438
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 432
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 431
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 428
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma 424
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 417
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 413
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy 409
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. 402
Phase I study of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with peritoneal carcinosis 400
MSC and Tumors: Homing, Differentiation and Secretion Influence The Therapeutic Potentials 397
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 392
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study 391
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing 391
Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood 389
Neoadjuvant treatment with Single – Agent Cetuximab Followed by 5-Fu, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer. 385
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 383
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 382
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 380
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 379
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 378
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 372
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 364
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 364
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 360
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.. 357
Mesenchymal progenitors aging highlights a mir-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis 356
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 354
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 352
Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM 349
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 345
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer 343
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 340
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 338
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria 336
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial 335
Achievements and unmet needs in the management of advanced ovarian cancer 333
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer 330
METHOD FOR PRODUCTION OF ANTI-TUMOR TRAIL PROTEIN 326
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 326
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. 326
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 324
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 323
Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy 323
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 321
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 318
Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation 316
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 312
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 311
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 311
Immune characterization of breast cancer metastases: prognostic implications. 310
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 310
Laparoscopic approach of gastric gastrointestinal stromal tumors (GISTs): Is it still a courageous choice? Report of two cases 309
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 309
5-Fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: A randomized phase II study in metastatic colorectal cancer 308
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 307
A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. 300
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 298
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 297
Donor Cell-Derived Osteopoiesis Originates from a Self-Renewing Stem Cell with a Limited Regenerative Contribution after Transplantation 297
Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer 296
Primary adrenal gland carcinosarcoma associated with metastatic rectal cancer: a hitherto unreported collision tumor 293
Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer 291
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region. 291
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer 285
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 284
Significance of lymph node sampling in epithelial carcinoma of the ovary. 283
Gastrointestinal stromal tumor and other primary metachronous and synchronous neoplasms as a suspicious criterion for syndromic setting 281
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 277
Prognostic value of "Dworak" tumor regression grade (TRG) after pre-operative chemo-radiotherapy in rectal cancer (RC) 277
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 275
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 273
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of After-6 protocol 1 273
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. 273
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. 271
Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A randomized trial of the Gruppo Oncologico Nord Ovest. 269
Cardiotoxicity of Epirubicin/Paclitaxel Containing Regimens: Role of Cardiac Risk Factors 267
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 267
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 266
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 266
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 265
The curability of breast cancer and the treatment of advanced disease 265
Paclitaxel and vinorelbine in anthracycline pretreated breast cancer: a phase II study. 263
Device for cell culture 263
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. 262
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG 261
Biomarkers predicting clinical benefit: fact or fiction? 258
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 258
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 254
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 254
41. HER2+ EARLY BREAST CANCER: DO WE HAVE ALL THE NECESSARY ANSWERS? 252
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 252
A phase II study with danazol in metastatic breast cancer. 252
Biomarker expression and survival after primary chemotherapy for breast cancer. 252
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 249
Timing for starting second-line therapy in recurrent ovarian cancer 248
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. 247
Totale 33.270
Salva come PNG Salva come JPEG
Categoria #
all - tutte 319.065
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 319.065
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20226.101 0 924 783 382 147 258 442 324 644 466 954 777
2022/20236.309 736 566 314 504 655 900 77 538 1.514 83 257 165
2023/20243.754 182 244 204 227 702 349 392 698 125 114 163 354
2024/202511.449 361 158 182 869 2.130 1.803 492 755 1.472 776 1.017 1.434
2025/202625.828 1.320 993 2.210 2.999 3.353 2.020 2.803 1.429 2.160 2.619 2.168 1.754
2026/20271.776 1.010 766 0 0 0 0 0 0 0 0 0 0
Totale 83.879